Ron Squarer is a global biopharmaceutical leader with extensive oncology commercialization expertise.
Mr. Squarer served as Chief Executive Officer and a member of the Board of Directors of Array BioPharma, Inc. from 2012 until 2019, during which time he executed an oncology-focused research, development, and commercialization strategy that culminated in the successful commercial launches of Braftovi® (encorafenib) and Mektovi® (binimetinib). During his tenure at Array, the company’s market capitalization grew more than 30-fold, and the company was ultimately acquired by Pfizer Inc. at a total enterprise value of approximately $11.4 billion.
Before joining Array, Mr. Squarer held positions of increasing responsibility with Hospira, Inc., a global pharmaceutical and medical device company. As Senior Vice President and Chief Commercial Officer at Hospira, he was responsible for delivering $4 billion in annual revenue. Mr. Squarer joined Hospira from Mayne Pharma, when it was sold to Hospira in 2007. Before serving as Senior Vice President, Global Corporate and Business Development at Mayne Pharma, Mr. Squarer held leadership roles at both Pfizer (focused on oncology) and SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) in the US and Europe.
Mr. Squarer currently serves as a member of the Board of Directors of Deciphera Pharmaceuticals, Inc. and Retrophin, Inc. He earned an MBA from the Kellogg School of Management, Northwestern University, and a Bachelor’s Degree in Biochemistry from the University of California, Berkeley.